SCYNEXIS (SCYX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
25 Jun, 2026Opening remarks and agenda
Meeting commenced with introductions of board members, executive officers, and the auditor present.
Formal business followed the agenda outlined in the notice and proxy statement.
Corporate governance
Quorum established with proxies for 74.49% of outstanding shares, allowing business to proceed.
No additional shareholder proposals were filed; business limited to six proxy proposals.
Scott Sukenick appointed as Inspector of Election for the meeting.
Shareholder proposals
Six proposals presented: election of directors, ratification of auditor, advisory vote on executive compensation, advisory vote frequency, amendment to equity incentive plan, and amendment to certificate of incorporation to increase authorized shares.
Partial view of Summaries dataset, powered by Quartr API
Latest events from SCYNEXIS
- SCY-770 and BARDA-backed SCY-247 advance toward Phase II with runway into 2029.SCYX
3rd Annual Guggenheim Healthcare Innovation Conference - SCY-770 advances toward ADPKD Phase 2 with cash runway into 2029.SCYX
Corporate presentation - SCY-770 enters ADPKD Phase 2 as SCY-247 advances with up to $214M in BARDA support.SCYX
Corporate presentation - A $200 million shelf backs a clinical pipeline facing funding and development risks.SCYX
Registration filing - Clinical progress and BARDA funding support Phase 2 plans, with runway into 2029.SCYX
Q3 2026 - SCY-770 advances toward ADPKD proof-of-concept, with cash runway into 2029.SCYX
Corporate presentation - Phase II trial of SCY-770 for ADPKD to launch by year-end, targeting major unmet need.SCYX
12th Annual Cantor Fitzgerald Global Healthcare Conference - Q2 2026 net income was $7.4M, with strong cash reserves and key clinical milestones ahead.SCYX
Q2 2026 - Shareholders approved a reverse stock split and reduction of authorized shares.SCYX
EGM 2026